Pembrolizumab is a humanized IgG4 monoclonal antibody and is the second anti-PD-1-antibody that has been approved for a variety of solid cancers and is currently under investigation for its use in HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.